In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laneur Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram...
All content for The Lancet Neurology in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laneur Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram...
In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laneur Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram...
